Navigation Links
Galectin Therapeutics: Turning Atlanta into America's Next Silicon Valley
Date:4/4/2013

NORCROSS, Ga., April 4, 2013 /PRNewswire/ -- Gilbert Amelio , former CEO of Apple, and Rod Martin , former counsel to PayPal, both on the Board of Directors of Galectin Therapeutics (NASDAQ: GALT) authored an opinion piece in today's Atlanta Journal Constitution discussing the future of Atlanta as the emerging Silicon Valley for changing the world by curing the big diseases, and why they moved Galectin Therapeutics to Atlanta.

"The world needs a biotech Silicon Valley. We believe that Atlanta is perfectly poised to become just that," wrote Amelio and Martin.

To read the full op-ed from the Atlanta Journal-Constitution, click here. To schedule interviews with Gil Amelio and Rod Martin , please contact Cheri Jacobus at cherijacobus@aol.com, or (202) 257-4638.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.  We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development.  We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.  Additional information is available at www.galectintherapeutics.com.


'/>"/>
SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
3. Turning smartphones into secure and versatile keys
4. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
5. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
6. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
7. A Homegrown Smile? Atlanta Dentist Examines New Research on the Biological Teeth Replacement
8. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
9. Avocado Oil: The Olive Oil Of The Americas?
10. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
11. Researching graphene nanoelectronics for a post-silicon world
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Vermillion, Inc. (NASDAQ: VRML), a bio-analytical ... its results for the fourth quarter and full ... marked a pivotal year for us with our ... distribution agreements, major reimbursement progress with Medicare, positive ... In addition we cleared our 2 nd ...
(Date:3/29/2017)... "Surging application of gesture control features in ... expected to drive the growth of gesture recognition and ... is expected to be worth USD 18.98 billion by ... and 2022. The touchless sensing market is expected to ... a CAGR of 17.44% between 2017 and 2022. Gesture ...
(Date:3/29/2017)... , March 29, 2017 WuXi Biologics, ... company dedicated to biologics and a WuXi AppTec ... 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, ... Excellence Awards aims to recognize outstanding leaders and ... Featuring top bioprocessing and biomanufacturing experts in the ...
(Date:3/29/2017)... ... March 29, 2017 , ... (March 29, 2017) — ... approved as an active member of the Mexican Direct Selling Association A.C. ... consumers in relationship marketing. This professional organization fosters loyal and fair competition among ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
Breaking Biology News(10 mins):